ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma (ABC-103)
A Phase Ib/II Safety and Efficacy Study of ABC294640 in Patients With Refractory or Relapsed Multiple Myeloma Who Have Previously Been Treated With Proteasome Inhibitors and Immunomodulatory Drugs
Sponsor: Apogee Biotechnology Corporation
Terminated
Expiration of National Cancer Institute (NCI) funding of the study.
Listed as NCT02757326, this PHASE1/PHASE2 trial focuses on Multiple Myeloma and remains terminated or withdrawn. Sponsored by Apogee Biotechnology Corporation, it has been updated 11 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE1_PHASE2
-
Sep 2021 — Dec 2022 [monthly]
Terminated PHASE1_PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2019 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
-
Jun 2018 — Jun 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Mar 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Apogee Biotechnology Corporation
- Duke University
- National Cancer Institute (NCI)
- RedHill Biopharma Limited
For direct contact, visit the study record on ClinicalTrials.gov .